Literature DB >> 9669428

In situ upregulation of IL-10 reflects the activity of human glomerulonephritides.

Z I Niemir1, M Ondracek, G Dworacki, H Stein, R Waldherr, E Ritz, H F Otto.   

Abstract

A reciprocal regulation between the expression of tumor necrosis factor (TNF)-alpha and interleukin (IL)-10, demonstrated in monocytes and mesangial cells, provides a rationale for new therapeutic approaches in glomerulonephritis (GN). Administration of IL-10 to mice with antibody-mediated GN attenuated the severity of glomerular lesions. Recently, however, it has been shown that the genetically determined predominance of Th1 or Th2 cytokines results in different glomerular responses to the same planted antigen, but in an equally severe impairment of renal function. We looked for the expression of IL-10 and TNF-alpha in 111 renal biopsy specimens with proliferative and nonproliferative forms of GN and in 10 control kidneys, by means of immunocytochemistry, in situ hybridization, or reverse-transcriptase polymerase chain reaction (RT-PCR). Six patients had acute endocapillary GN (AGN), 10 patients had pauci-immune GN due to microscopic polyangiitis (MP), 48 patients had immunoglobulin-A (IgA)-GN, 18 patients had idiopathic membranous GN (IMGN), 12 patients had minimal change disease (MCD), and 13 patients had focal segmental glomerulosclerosis (FSGS) and four other forms of GN. Antibodies against monocytes (CD14) and macrophages (CD68) were applied to attribute the expression of TNF-alpha and IL-10 to resident renal or infiltrating cells. We show that mRNAs for TNF-alpha and IL-10 are detected by RT-PCR and in situ hybridization in the normal kidney. A constitutive expression of TNF-alpha protein is observed in mesangial cells, smooth muscle cells in renal arteries, and in the interstitium. A trace immunoreactivity for IL-10 is restricted to arterial smooth muscle cells, distal tubular epithelial cells, and some interstitial cells. Upregulation of both cytokines is found in glomerular diseases. The expression of TNF-alpha increases in mesangial areas in MCD, IMGN stages I/II, and IgA-GN with minor glomerular abnormalities, that is, under conditions with a generally well-preserved glomerular structure. Conversely, marked glomerular proliferation in IgA-GN and, particularly, acute vascular lesions in MP, are accompanied by a significant upregulation of IL-10 (at the mRNA and protein level). Patients with nephrotic-range proteinuria show a significant increase in tubulointerstitial expression of IL-10, whereas the immunoreactivity for TNF-alpha reflects the extent of interstitial fibrosis. Thus, our results confirm previous suggestions that proinflammatory and antiinflammatory cytokines are produced in situ by resident renal cells and contribute to the natural course of human GN.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9669428     DOI: 10.1053/ajkd.1998.v32.pm9669428

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  12 in total

1.  Regulation of pathogenic Th17 cell differentiation by IL-10 in the development of glomerulonephritis.

Authors:  Ruihua Zhang; Qin Li; Peter Y Chuang; Geming Lu; Ruijie Liu; Jianjun Yang; Liang Peng; Yan Dai; Zihan Zheng; Chen-Feng Qi; John Cijiang He; Huabao Xiong
Journal:  Am J Pathol       Date:  2013-06-05       Impact factor: 4.307

2.  Interleukin-10 inhibits experimental mesangial proliferative glomerulonephritis.

Authors:  A R Kitching; M Katerelos; S J Mudge; P G Tipping; D A Power; S R Holdsworth
Journal:  Clin Exp Immunol       Date:  2002-04       Impact factor: 4.330

Review 3.  Role of IL-10 in the progression of kidney disease.

Authors:  Inna Sinuani; Ilia Beberashvili; Zhan Averbukh; Judith Sandbank
Journal:  World J Transplant       Date:  2013-12-24

4.  Tumor necrosis factor-alpha production from mononuclear cells in nephrotic syndrome.

Authors:  Ashraf Bakr; Mohamed Shokeir; Farha El-Chenawi; Fatma El-Husseni; Ashraf Abdel-Rahman; Rasha El-Ashry
Journal:  Pediatr Nephrol       Date:  2003-04-18       Impact factor: 3.714

5.  Renal vein cytokine release as an index of renal parenchymal inflammation in chronic experimental renal artery stenosis.

Authors:  Alfonso Eirin; Xin Zhang; Xiang-Yang Zhu; Hui Tang; Kyra L Jordan; Joseph P Grande; Allan B Dietz; Amir Lerman; Stephen C Textor; Lilach O Lerman
Journal:  Nephrol Dial Transplant       Date:  2013-10-03       Impact factor: 5.992

6.  Interleukin-10 promoter polymorphism is associated with the predisposition to the development of IgA nephropathy and focal segmental glomerulosclerosis in Korea.

Authors:  Ho Jun Chin; Ki Young Na; Soo Jin Kim; Kook-Hwan Oh; Yon Su Kim; Chun Soo Lim; Suhnggwon Kim; Dong-Wan Chae
Journal:  J Korean Med Sci       Date:  2005-12       Impact factor: 2.153

7.  Phase 1 trial of adalimumab in Focal Segmental Glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) study group.

Authors:  Melanie S Joy; Debbie S Gipson; Leslie Powell; Jacqueline MacHardy; J Charles Jennette; Suzanne Vento; Cynthia Pan; Virginia Savin; Allison Eddy; Agnes B Fogo; Jeffrey B Kopp; Daniel Cattran; Howard Trachtman
Journal:  Am J Kidney Dis       Date:  2009-11-22       Impact factor: 8.860

8.  Parenchymal organ, and not splenic, immunity correlates with host survival during disseminated candidiasis.

Authors:  Brad Spellberg; Douglas Johnston; Quynh Trang Phan; John E Edwards; Samuel W French; Ashraf S Ibrahim; Scott G Filler
Journal:  Infect Immun       Date:  2003-10       Impact factor: 3.441

9.  BK virus infection activates the TNFα/TNF receptor system in Polyomavirus-associated nephropathy.

Authors:  Andrea Ribeiro; Monika Merkle; Nasim Motamedi; Hans Nitschko; Simone Köppel; Markus Wörnle
Journal:  Mol Cell Biochem       Date:  2015-10-07       Impact factor: 3.396

10.  Th1, Th2 and Treg/T17 cytokines in two types of proliferative glomerulonephritis.

Authors:  M Stangou; C Bantis; M Skoularopoulou; L Korelidou; D Kouloukouriotou; M Scina; I T Labropoulou; N M Kouri; A Papagianni; G Efstratiadis
Journal:  Indian J Nephrol       Date:  2016 May-Jun
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.